<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106703</url>
  </required_header>
  <id_info>
    <org_study_id>A060655</org_study_id>
    <nct_id>NCT01106703</nct_id>
  </id_info>
  <brief_title>The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels</brief_title>
  <official_title>The Effects of PG102 on Allergy-related Risk Factors: A Randomized, Double Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the efficacy of PG102 at lowering levels of total IgE
      in asymptomatic subjects with atopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum total IgE level</measure>
    <time_frame>8weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum level of allergy-related factors, such as eosinophilic cation protein(ECP), eotaxin, thymus, and activation-regulated chemokine (TARC), IL-4, IL-5, and IL-13, skin test(atopy score), and adverse reactions</measure>
    <time_frame>8weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Asymptomatic Subjects With Atopy and Elevated Serum IgE</condition>
  <arm_group>
    <arm_group_label>PG102 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PG102, a water soluble extract from Actinidia arguta</intervention_name>
    <description>PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks</description>
    <arm_group_label>PG102 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects who have atopy but no allergy-related symptoms

          -  subjects with total IgE levels of 300IU/ml or more

          -  acquisition of written informed consent prior to commencement of study

          -  no serious clinical symptoms and normal laboratory test results; in case of abnormal
             finding, subjects whose conditions are not deemed severe from the judgement of
             investigators

        Exclusion Criteria:

          -  individuals with normal levels of total serum IgE

          -  ue of one or more allergic drugs

          -  serious clinical conditions (such as malignancies, severe cardiovascular disease etc.)

          -  serious mental disorder

          -  pregnant woman or woman of childbearing potential within 3 months

          -  subjects who participated in other clinical trials in the past 6months

          -  individuals who have a plan to participate in another clinical trials during this
             trial

          -  subjects with a history of kiwi allergy

          -  subjects whose conditions are inappropriate by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Up Min, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soeul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>July 23, 2010</last_update_submitted>
  <last_update_submitted_qc>July 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seoul National University Hospital</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>atopy, IgE</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

